Prof. Dr. Henning Walczak - Curriculum Vitae
Education and Professional Career
since 2026: PI at the Center for Molecular Medicine Cologne
since 2019: Alexander von Humboldt Professor of Biochemistry and Director of the Institute of Biochemistry I, Medical Faculty, University of Cologne, Germany
since 2013: Professor of Cancer Biology and Chair of the Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, London, UK
2014 – 2019: Head of the Department of Cancer Biology, UCL Cancer Institute, London, UK
2013 – 2019: Scientific Director of the Cancer Research UK–UCL Cancer Centre
2007 – 2012: Professor of Tumour Immunology, Imperial College London, London, UK
2000 – 2007: Head of BioFuture Group “Apoptosis Regulation”, Tumour Immunology Programme, DKFZ, Heidelberg, Germany
2002 – 2004: CEO/CSO of Apogenix
1998 – 2000: Group Leader in the Tumour Immunology Programme, DKFZ
1996 – 1997: Scientist (PostDoc Level) at Immunex Corp. in Seattle, WA, USA
1995 – 1996: Postdoctoral Fellow, Tumour Immunology Programme, DKFZ
1992-1995: Dr. rer. nat. (summa cum laude), conducted at the Department of Immunogenetics, Tumour Immunology Programme, DKFZ, Heidelberg, Germany (degree awarded by University of Bielefeld)
1986-1992: Studies of Biology at the University of Bielefeld, Germany, with master thesis conducted at DKFZ
Awards, Distinctions and Scientific Activities
since 2023: Spokesperson of the Key Profile Area “Cancer Ecosystems” of the University of Cologne, one of nine University-wide research networks of excellence
since 2022: Spokesperson of the “CANcer TARgeting” (CANTAR) Research Network, a state-wide cancer research network of excellence funded by the state of North-Rhine Westfalia (NRW)
2019: Alexander von Humboldt Professorship Prize
2018: Wellcome Trust Investigator Award
2012: Wellcome Trust Investigator Award
2011: ERC Advanced Grant
2001: Genius biotech Award (1st Prize) for business plan of Apogenix
1999: BioFuture Prize (BMBF)